Drug Profile
Research programme: kinase inhibitors - Galapagos/Teijin
Alternative Names: Kinase inhibitors research programme - BioFocus/TeijinLatest Information Update: 13 Apr 2007
Price :
$50
*
At a glance
- Originator Galapagos NV; Teijin Pharma
- Class Small molecules
- Mechanism of Action Phosphotransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 13 Apr 2007 No development reported - Preclinical for Inflammation (unspecified route)
- 04 Nov 2005 BioFocus has been acquired and merged into Galapagos NV
- 17 Jun 2004 Teijin has acquired global rights to develop and market anti-inflammatory drug leads from the collaboration